GENEVA (AP) — The World Health Organization has authorized the first mpox vaccine for children, a decision experts hope will help make immunizations more widely available to one of the hardest-hit populations during the ongoing outbreaks of the disease in Congo and elsewhere in Africa. In a statement late Tuesday, the U.N.
health agency said it had approved the mpox vaccine made by Japanese company KM Biologics for use in children over 1 year of age as a single dose. Earlier this month, the charity Save the Children said that cases among children younger than 18 had increased by more than 130% in Congo, noting there were now more than 25,000 suspect cases. The charity said that children were almost four times more likely than adults to die from the first detected in eastern Congo earlier this year.
Mpox, related to smallpox, mostly causes symptoms including fever, rash, lesions and fatigue. “Children are especially vulnerable to mpox,” Save The Children’s Dr. Katia Vieira de Moraes LaCasse said in a statement.
“They explore by touch and taste, don’t always understand health guidance and have weaker immune systems than adults.” Scientists have previously noted that mpox appears to be disproportionately affecting children in Congo and Burundi, which account for more than 90% of all mpox cases in Africa’s current outbreak. WHO had previously approved the mpox vaccine made by Bavarian Nordic for people 18 and over, but said that the shot could be used in younger p.
